 |
|
|
| |
Postpartum weight changes in women initiating DTG vs EFV in pregnancy: DolPHIN-2
|
| |
| |
CROI 2020: SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (04/10/20)
DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ (04/04/20)
ADVANCE Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - (03/12/20)
200+ NATAP CROI reports:
Conference on Retroviruses and Opportunistic Infections
Boston USA
March 8-11, 2020
CROI 2020
Thokozile R. Malaba1, Tao Chen2, Kenneth Kintu3, Christiana Papamichael2, Helen Reynolds4, Jesca Nakibuka3, Catriona Waitt3,4, Eva Maria Hodel4, Angela Colbers5, Catherine Orrell6, Duolao Wang2, Mohamed Lamorde3,
Saye Khoo4, Landon Myer1, for the DolPHIN-2 trial team
1Division of Epidemiology & Biostatistics, University of Cape Town, Cape Town, South Africa, 2Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 3Infectious Diseases Institute, Makerere University,
Kampala, Uganda , 4University of Liverpool, Liverpool, United Kingdom, 5Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands, 6Desmond Tutu HIV Centre, Department of Medicine, Institute
of Infectious Diseases & Molecular Medicine, University of Cape Town, Cape Town, South Africa
http://www.croiwebcasts.org/console/player/44620?mediaType=audio&
|
| |
|
|
|
|
|
